Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, HSP, PSF

Blue Shield of California Announces California's COVID-19 Vaccine Network with Capacity to Administer 5.5 Million Doses per Week


OAKLAND, Calif., March 31, 2021 /PRNewswire/ -- Blue Shield of California, the state of California's third-party administrator, today announced it has successfully transitioned the state's enhanced COVID-19 vaccine provider network that can administer 5.5 million doses a week to help save more lives.

The dramatically increased capacity is the result of collaboration among state health officials, local health jurisdictions and nearly 300 providers throughout the state that operate some 2,200 vaccination sites.

The network reaches more than 99 percent of Californians, and 99 percent of those who live in the Healthy Places Index lowest quartile areas, based on the state's requirement of access to providers within 10 miles in urban areas and 30 miles in rural areas.

"Equitable distribution of the vaccine is a top priority for the state of California and we have made great progress in building a statewide system that supports that goal," said Paul Markovich, president & CEO, Blue Shield of California. "There's still more work to do as more providers and local health jurisdictions join the statewide network. Together we can overcome this pandemic and save more lives, especially Californians living in the most vulnerable communities."

California continues to build positive momentum as it readies to receive increased supply of COVID-19 vaccines from the federal government in the coming weeks.

In addition to building the state's capacity to administer 5.5 million doses a week, other key milestones include:

It's important to note that providers whose patients are awaiting second doses will continue to receive vaccine allocation from the state in order to complete those vaccinations. In addition, Blue Shield will continue to onboard eligible providers who are interested in participating in the state's enhanced network to help ensure vaccines are available to as many Californians as possible.

The latest list of participating vaccine providers can be found at this link.

Blue Shield is a nonprofit health plan that's answering the call by the state to support its vaccine distribution efforts to help save lives. The health plan is working closely with each county, its public health leaders, and state officials to build a vaccine network to help meet the state's goal to ensure all Californians have access to the vaccines equitably, efficiently and as quickly as possible.

The health plan is taking on this effort at cost without making a profit from the state. Blue Shield is not charging the state for its staff time devoted to this effort. It will only bill the state actual expenses to support the network up to the limit of the contract.

More information about Blue Shield's support of the state's efforts can be found at this link.

About Blue Shield of California

Blue Shield of California strives to create a healthcare system worthy of its family and friends that is sustainably affordable. Blue Shield of California is a tax paying, nonprofit, independent member of the Blue Shield Association with over 4.5 million members, over 7,500 employees and more than $21 billion in annual revenue. Founded in 1939 in San Francisco and now headquartered in Oakland, Blue Shield of California and its affiliates provide health, dental, vision, Medicaid and Medicare healthcare service plans in California. The company has contributed more than $150 million to Blue Shield of California Foundation in the last four years to have an impact on California communities.

For more news about Blue Shield of California, please visit news.blueshieldca.com.

Or follow us on LinkedIn, Twitter, or Facebook.

###

CONTACT:

Erika Conner


Blue Shield of California


510-607-2359


media@blueshieldca.com

 

SOURCE Blue Shield of California


These press releases may also interest you

at 06:50
New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca's datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC), showed preliminary response and disease control in patients with...

at 05:57
Delic Holdings Inc. ("DELIC" or the "Company") , a psychedelic wellness-focused company, announces that the Company is not aware of any material undisclosed information and wishes to make the following statements regarding recent sponsored news and...

7 mai 2021
The global moist wound dressings market is set to grow by USD 1.25 billion during 2021-2025, registering a CAGR of almost 6%. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the...

7 mai 2021
Goldenway International Trade Co., Ltd. is recalling Golden Mushroom brand Enoki Mushroom from the marketplace due to possible Listeria monocytogenes contamination. Consumers should not consume the recalled product described below. The following...

7 mai 2021
The hemodialysis equipment market is expected to grow by USD 3.57 billion during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the hemodialysis equipment market in optimistic, probable,...

7 mai 2021
The clinical laboratory workforce that underpins the U.S. healthcare system is under siege. As the providers of critical information to patient and medical providers to diagnose, treat, and manage disease, the number of laboratory professionals in...



News published on 31 march 2021 at 17:06 and distributed by: